Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Gains from Investment Securities (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Gains from Investment Securities for 7 consecutive years, with $3.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 6.21% to $3.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.8 million, a 6.21% decrease, with the full-year FY2024 number at $9.4 million, down 6.19% from a year prior.
  • Gains from Investment Securities was $3.8 million for Q3 2025 at Fulcrum Therapeutics, down from $12.1 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $12.3 million in Q1 2024 to a low of -$813000.0 in Q4 2024.
  • A 5-year average of $3.9 million and a median of $2.0 million in 2022 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: plummeted 108.15% in 2024, then soared 7978.9% in 2025.
  • Fulcrum Therapeutics' Gains from Investment Securities stood at $500000.0 in 2021, then soared by 1200.82% to $6.5 million in 2022, then surged by 53.32% to $10.0 million in 2023, then tumbled by 108.15% to -$813000.0 in 2024, then skyrocketed by 568.18% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Gains from Investment Securities are $3.8 million (Q3 2025), $12.1 million (Q2 2025), and $233117.0 (Q1 2025).